Jan Pofer A. Mantos, Portia Menelia D. Monreal, Rebecca A. Castro, Caroline Anne A. Castro
Apr 2023 DOI 10.35460/2546-1621.2021-0155 Access
Background: Apart from its role in bone health, recent developments have shown that vitamin D also has anti-inflammatory properties, and therefore may have a role in inflammatory bowel disease (IBD) in children.
Objectives: To determine the effect of vitamin D supplementation on the disease activity of pediatric patients with IBD.
Design: Random-effects meta-analysis
Data Sources: Studies were searched at Cochrane Library, PubMed, EBSCO Host, ScienceDirect, Google Scholar, and Wiley Online.
Review Methods: Experimental studies measuring the effect of vitamin D on the disease activity of pediatric patients with IBD were included. The proportion of disease activity, measured as remission rate or inactivity using Pediatric Crohn’s Disease Activity Index (PCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI), and the mean and standard deviation of mean serum vitamin D [25(OH)D] level, change in 25(OH)D, and different inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] were extracted or estimated and recorded in an abstraction form. Standardized mean difference and odds ratio were used as summary effect measures and estimated using Stata/Multiprocessor.
Results: The serum 25(OH)D (SMD = 1.75, z = 2.33, p = 0.001) and change in 25(OH)D (SMD = 3.37, z = 2.34, p = 0.019) was significantly higher among those who received a high dose of vitamin D. However, a significantly high heterogeneity was estimated (I2 >50%). For the disease activity of IBD, the standard mean difference of mean ESR (SMD = –1.10, z = 5.35, p = 0.001) was significantly lower with high-dose vitamin D. The likelihood of remission rate using the Pediatric Crohn’s Disease Activity Index (PCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI), and standardized mean difference of CRP were not significantly different among those who received high-dose and low-dose vitamin D.
Conclusion: Cognizant of the functions of vitamin D in enhancing intestinal flora balance, regulating immunologic response, and improving intestinal mucosal barrier, vitamin D can be recommended as a supplementary treatment for IBD among the pediatric population. Nevertheless, there is still insufficient evidence for the cut-off level of adequate levels of serum 25(OH)D among pediatric patients with IBD, thus necessitating further studies.
Key words: Vitamin D therapy, Pediatric Inflammatory Bowel Disease, Vitamin D deficiency
- Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science [Internet]. 1983;221(4616):1181–3. Available from: http://dx.doi.org/10.1126/science.6310748
- Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol [Internet]. 2006;92(1):60–4. Available from: http://dx.doi.org/10.1016/j.pbiomolbio.2006.02.020
- Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis [Internet]. 2006;12:S3–9. Available from: http://dx.doi.org/10.1097/01.mib.0000195385.19268.68
- Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature [Internet]. 2011;474(7351):307–17. Available from: http://dx.doi.org/10.1038/nature10209
- Raman M, Milestone AN, Walters JRF, Hart AL, Ghosh S. Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap Adv Gastroenterol [Internet]. 2011;4(1):49–62. Available from: http://dx.doi.org/10.1177/1756283X10377820
- Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25 (OH) vitamin D level in Crohn’s disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130(2):133–7.
- Blanck S, Aberra F. Vitamin D deficiency is associated with ulcerative colitis disease activity. Dig Dis Sci [Internet]. 2013;58(6):1698–702. Available from: http://dx.doi.org/10.1007/s10620-012-2531-7
- Schünemann H, Brożek J, Guyatt G, Oxman A. Introduction to GRADE handbook: Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. The GRADE Working Group; October 2013.
- El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci [Internet]. 2011;56(3):825–9. Available from: http://dx.doi.org/10.1007/s10620-010-1380-5
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ [Internet]. 2003;327(7414):557–60. Available from: http://dx.doi.org/10.1136/bmj.327.7414.557
- Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol [Internet]. 2014;20(33):11525–37. Available from: http://dx.doi.org/10.3748/wjg.v20.i33.11525
- Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol [Internet]. 2007;23(4):365–9. Available from: http://dx.doi.org/10.1097/MOG.0b013e3281c55eb2
- Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25 dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35(1):217–24.
- Verlinden L, Leyssens C, Beullens I, Marcelis S, Mathieu C, De Clercq P, et al. The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease. J Steroid Biochem Mol Biol [Internet]. 2013;136:107–11. Available from: http://dx.doi.org/10.1016/j.jsbmb.2012.09.017
- Goff JP, Koszewski NJ, Haynes JS, Horst RL. Targeted delivery of vitamin D to the colon using glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2012;302:G460-469.
- Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease - a randomized double-blind placebo-controlled study: Clinical trial: vitamin D and Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2010;32(3):377–83. Available from: http://dx.doi.org/10.1111/j.1365-2036.2010.04355.x
- Li J, Chen N, Wang D, Zhang J, Gong X. Efficacy of vitamin D in treatment of inflammatory bowel disease. Medicine (Baltimore). 2018;97(46):e12662.
- Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, Nedjat S. A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients. Saudi J Gastroenterol [Internet]. 2016;22(4):316–23. Available from: http://dx.doi.org/10.4103/1319-3767.187606
- Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther [Internet]. 2014;39(2):125–36. Available from: http://dx.doi.org/10.1111/apt.12553
- Nicholson I, Dalzell AM, El-Matary W. Vitamin D as therapy for colitis: A systemic review. J Crohns Colitis. 2012;6(4):405–11.
- Karimi S, Tabataba-Vakili S, Yari Z, Alborzi F, Hedayati M, Ebrahimi-Daryani N, et al. The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status. Nutr J [Internet]. 2019;18(1):16. Available from: http://dx.doi.org/10.1186/s12937-019-0441-7
- Nielsen OH, Hansen TI, Gubatan JM, Jensen KB, Rejnmark L. Managing vitamin D deficiency in inflammatory bowel disease. Frontline Gastroenterol [Internet]. 2019;10(4):394–400. Available from: http://dx.doi.org/10.1136/flgastro-2018-101055
- Simek RZ, Prince J, Syed S, Sauer CG, Martineau B, Hofmekler T, et al. Pilot study evaluating efficacy of two dosing regimens for repletion of hypovitaminosis D in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62(2):252–8.
- Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J [Internet]. 2005;19(9):1067–77. Available from: http://dx.doi.org/10.1096/fj.04-3284com
- Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin β2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285(4):2227–31.
- Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol [Internet]. 2008;8(9):685–98. Available from: http://dx.doi.org/10.1038/nri2378
- Feng YJ, Li YY. The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease: Role of p38 MAPK in IBD. J Dig Dis [Internet]. 2011;12(5):327–32. Available from: http://dx.doi.org/10.1111/j.1751-2980.2011.00525.x
- Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med [Internet]. 2004;351(20):2069–79. Available from: http://dx.doi.org/10.1056/NEJMoa033402
- Zhang Y, Leung D, Richers BN, Liu Y, Remigio LK, Riches DW. Vitamin D inhibits monocyte/macrophage pro-inflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–35.
- Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012;12:57.
Articles related to the one you are viewing
There are currently no results to show, please try again later
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.